12/23
07:03 pm
sgmt
We're Hopeful That Sagimet Biosciences (NASDAQ:SGMT) Will Use Its Cash Wisely [Yahoo! Finance]
Low
Report
We're Hopeful That Sagimet Biosciences (NASDAQ:SGMT) Will Use Its Cash Wisely [Yahoo! Finance]
12/19
02:43 pm
sgmt
Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market [Seeking Alpha]
Medium
Report
Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market [Seeking Alpha]
12/18
07:32 am
sgmt
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination [Yahoo! Finance]
Medium
Report
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination [Yahoo! Finance]
12/18
07:00 am
sgmt
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
Medium
Report
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
12/17
07:56 am
sgmt
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet's Fixed Dose Combination Program [Yahoo! Finance]
Low
Report
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet's Fixed Dose Combination Program [Yahoo! Finance]
12/17
07:00 am
sgmt
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
Medium
Report
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
12/10
07:39 am
sgmt
Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration [Yahoo! Finance]
Low
Report
Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration [Yahoo! Finance]
12/10
07:03 am
sgmt
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
Low
Report
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
12/10
04:15 am
sgmt
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
Low
Report
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
12/10
04:15 am
sgmt
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
Low
Report
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
12/9
04:15 pm
sgmt
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
12/9
04:05 pm
sgmt
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/22
02:11 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) was downgraded by analysts at
Wall Str
Low
Report
Sagimet Biosciences (NASDAQ:SGMT) was downgraded by analysts at
Wall Str
11/22
02:11 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) was downgraded by analysts at
Wall Str
Low
Report
Sagimet Biosciences (NASDAQ:SGMT) was downgraded by analysts at
Wall Str
11/20
07:50 am
sgmt
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference [Yahoo! Finance]
Medium
Report
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference [Yahoo! Finance]
11/20
07:00 am
sgmt
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
Medium
Report
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
11/18
05:53 am
sgmt
Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts [Seeking Alpha]
Low
Report
Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts [Seeking Alpha]
11/14
10:32 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) had its price target raised by analysts at Citizens Jmp from $33.00 to $35.00. They now have a "market outperform" rating on the stock.
Low
Report
Sagimet Biosciences (NASDAQ:SGMT) had its price target raised by analysts at Citizens Jmp from $33.00 to $35.00. They now have a "market outperform" rating on the stock.
11/14
07:53 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Sagimet Biosciences (NASDAQ:SGMT) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/14
07:22 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Sagimet Biosciences (NASDAQ:SGMT) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
11/13
12:07 pm
sgmt
Sagimet Biosciences GAAP EPS of -$0.40 misses by $0.01 [Seeking Alpha]
Low
Report
Sagimet Biosciences GAAP EPS of -$0.40 misses by $0.01 [Seeking Alpha]
11/13
07:30 am
sgmt
Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Medium
Report
Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
11/10
07:00 am
sgmt
Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025
High
Report
Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025
10/24
07:00 am
sgmt
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
High
Report
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
10/19
01:06 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) was upgraded by analysts at
Wall Stree
Medium
Report
Sagimet Biosciences (NASDAQ:SGMT) was upgraded by analysts at
Wall Stree